News

Fellows Shannon Miller and Megan Ken have both received NIH Director’s Awards from the NIH Common Fund’s High-Risk, High-Reward Research program.

The grant from the NIA/NIH will support research into how air pollution could lead to the development of Alzheimer’s disease.

Scripps Research scientists used knowledge about a protein to characterize drugs that selectively bind to its “twin,” or paralog.

The awards from the NIDDK and the LLHF will let Droujinine uncover how interorgan communication goes awry in metabolic disease and aging, paving the way for new treatments.

An international collaboration between Scripps Research, University of Arizona, CNRS and others provides additional analysis of how the pandemic began.

The novel method uses sets of four RNA nucleotides—rather than the natural three—to encode new, synthetic building blocks into proteins.

Using a combination of two protein-mapping methods, Scripps Research scientists uncover novel proteins that could be targeted by future cancer drugs.

Scripps Research scientists discovered a molecule produced by roundworm intestines that signals the brain to slow fat loss when food is not available. 

The building blocks can be used to create polymers with previously unexplored structures and fine-tunable properties, with applications across energy storage and more.

Scripps Research scientists showed that, with help from an AI tool, cardiologists can diagnose heart attacks using a simpler, easier and more accessible electrocardiogram technology.

Wearable health sensors are a powerful tool in disease detection and in stemming the spread of infections.

This honor from the Howard Hughes Medical Institute recognizes Ye’s “whole-body” approach to studying the how the brain functions in healthy versus diseased states.

Scripps Research launches digital trial to identify sleep-related risk factors for Alzheimer’s disease and other dementias using activity trackers.

A set of neurons identified by Scripps Research scientists influence the start of eating and drinking.

Study by Scripps Research scientists suggests future therapies for opioid and alcohol addiction.

The newly appointed faculty are making transformative discoveries in areas ranging across drug discovery, neuroscience, chemistry, immunity and more.

Across four preclinical studies, Scripps Research, IAVI, and additional collaborators make headway in stimulating the rare antibodies needed to fight HIV.

Scripps Research has appointed Professor Keary Engle to the role of Dean of Graduate and Postdoctoral Studies, effective July 1, 2024, and will lead the institute's Skaggs Graduate School of Chemical and Biological Sciences and other education and training programs.

Scripps Research scientists found that a “one-two punch” of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, including Hodgkin lymphoma.

Jin is named a 2024 Pew Scholar and receives the McKnight Scholar Award, supporting her research in mapping the genes and cell types in brain development.

Scripps Research’s vision to translate basic scientific discovery into effective treatments that benefit human health strikes a chord with Barbara Kosacz, JD—making her addition to the institution’s Board of Directors fitting.

Skaggs family also honored at commencement ceremony as first recipients of Scripps Research Presidential Medal

By recording detailed electrical and protein measurements of individual brain cells, researchers revealed new potential drug targets for the neurodegenerative disease.

Scripps Research scientists have developed a potential drug-like molecule that blocks the first stage of type A influenza infection.